Literature DB >> 12009777

Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA-lesioned rats.

Charles K Meshul1, Darlene Kamel, Cindy Moore, Tom S Kay, Lisa Krentz.   

Abstract

The overall goal of this study was to determine the effects of subchronic nicotine (0.4 mg/kg) treatment for 7 or 14 days on striatal glutamate function in both naïve and in 6-hydroxydopamine (6-OHDA)-treated rats in which the nigrostriatal dopamine pathway was lesioned. In lesioned animals, the effect of nicotine on apomorphine-induced contralateral rotations was also assessed. In naïve rats, once daily nicotine administration for 7 or 14 days resulted in a decrease and then an increase, respectively, in the basal extracellular level of striatal glutamate compared to the saline-treated group. Ultrastructurally, 14-day treatment with nicotine resulted in an increase in the density of striatal glutamate immunolabeling within nerve terminals making an asymmetrical synaptic contact compared to the saline-treated group. In 6-OHDA-lesioned animals, coadministration of nicotine with apomorphine or nicotine alone for 7 days resulted in an increase in the density of nerve terminal glutamate immunolabeling, compared to the apomorphine- or saline-treated groups. However, coadministration of nicotine with apomorphine for 14 days resulted in a decrease in the density of nerve terminal glutamate immunolabeling compared to the nicotine-treated group. Following subchronic treatment of 6-OHDA-lesioned rats with apomorphine for 7 or 14 days, there was an increase in the number of apomorphine-induced contralateral rotations compared to the saline treated group. There was a decrease in the number of apomorphine-induced contralateral rotations in the group coadministered nicotine with apomorphine for 7 or 14 days compared to the apomorphine treated group. The data suggests that in this 6-OHDA lesion model of Parkinson's disease, treatment with nicotine may be useful in counteracting the increased behavioral effect (i.e., contralateral rotations) observed after treatment with a dopamine agonist, such as apomorphine. Copyright 2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12009777     DOI: 10.1006/exnr.2002.7900

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  16 in total

Review 1.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

Review 2.  Mysterious alpha6-containing nAChRs: function, pharmacology, and pathophysiology.

Authors:  Ke-chun Yang; Guo-zhang Jin; Jie Wu
Journal:  Acta Pharmacol Sin       Date:  2009-06       Impact factor: 6.150

3.  5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease.

Authors:  Marcus C Ferguson; Tultul Nayyar; Ariel Y Deutch; Twum A Ansah
Journal:  Neuropharmacology       Date:  2010-03-31       Impact factor: 5.250

Review 4.  Nicotine and Parkinson's disease: implications for therapy.

Authors:  Maryka Quik; Kathryn O'Leary; Caroline M Tanner
Journal:  Mov Disord       Date:  2008-09-15       Impact factor: 10.338

5.  GABAA-benzodiazepine receptor availability in smokers and nonsmokers: relationship to subsyndromal anxiety and depression.

Authors:  Irina Esterlis; Kelly P Cosgrove; Jeffery C Batis; Frederic Bois; Tracy A Kloczynski; Stephanie M Stiklus; Edward Perry; Gilles D Tamagnan; John P Seibyl; Robert Makuch; Suchitra Krishnan-Sarin; Stephanie O'Malley; Julie K Staley
Journal:  Synapse       Date:  2009-12       Impact factor: 2.562

Review 6.  Glutamatergic substrates of drug addiction and alcoholism.

Authors:  Justin T Gass; M Foster Olive
Journal:  Biochem Pharmacol       Date:  2007-06-30       Impact factor: 5.858

7.  Genetic Knockdown of mGluR5 in Striatal D1R-Containing Neurons Attenuates L-DOPA-Induced Dyskinesia in Aphakia Mice.

Authors:  José-Rubén García-Montes; Oscar Solís; Juan Enríquez-Traba; Irene Ruiz-DeDiego; René Drucker-Colín; Rosario Moratalla
Journal:  Mol Neurobiol       Date:  2018-09-27       Impact factor: 5.590

Review 8.  Nicotinic receptors as CNS targets for Parkinson's disease.

Authors:  Maryka Quik; Tanuja Bordia; Kathryn O'Leary
Journal:  Biochem Pharmacol       Date:  2007-06-17       Impact factor: 5.858

9.  Nicotinic Receptor Intervention in Parkinson's Disease: Future Directions.

Authors:  Yousef Tizabi; Bruk Getachew
Journal:  Clin Pharmacol Transl Med       Date:  2017-03-06

10.  Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys.

Authors:  Luping Z Huang; Neeraja Parameswaran; Tanuja Bordia; J Michael McIntosh; Maryka Quik
Journal:  J Neurochem       Date:  2009-02-24       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.